Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence

Paula Jiménez-Fonseca,Enrique Gallardo, Fernando Arranz Arija, Jesús Manuel Blanco,Ana Callejo,Diego Cacho Lavin,Marinha Costa Rivas,Joaquín Mosquera,Alberto Rodrigo, Raúl Sánchez Morillas,María Vares Gonzaléz,Andrés Muñoz,Alberto Carmona-Bayonas

European Journal of Internal Medicine（2022）

引用 6|浏览11

暂无评分

摘要

•Thromboprophylaxis should be considered in patients with ALK/ROS1+ stage IV lung cancer requiring systemic treatment.•Cautiously reintroduce an effective antiangiogenic agent after thrombosis.•Anticoagulation should be maintained for >6 months in patients with metastatic cancer on active treatment.•If rethrombosis, rule out active cancer, infratherapeutic dose, or anticoagulation failure.•Treat thrombosis with LMWH not requiring dose titration (CrCl>30) or stop (CrCl<15).

查看译文

关键词

Venous thromboembolism,Cancer,Anticoagulation,Cancer-associated thrombosis,Prophylaxis,Treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要